AGE - AgeX Therapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
3.8600
-0.0500 (-1.28%)
As of 10:48AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.9100
Open3.9400
Bid2.7500 x 900
Ask0.0000 x 800
Day's Range3.7405 - 3.9600
52 Week Range1.1300 - 5.9500
Volume13,945
Avg. Volume79,050
Market Cap145.252M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2930
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wirelast month

    AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

    ALAMEDA, Calif.-- -- Published data in peer-reviewed scientific journal to advance potential cell therapy AgeX-BAT1 for Type II Diabetes and obesity Received $4.5 million from the exercise of warrants in March 2019 Presented at four industry and investor conferences AgeX Therapeutics , Inc. , a biotechnology company focused on therapeutics for human aging, reported financial and operating results for ...

  • Business Wire2 months ago

    AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute

    AgeX Therapeutics, Inc. , a biotechnology company focused on therapeutics for human aging, will participate at Biotech Investing in Longevity, an evening event from Aikora Health and Foresight Institute, on Wednesday, May 1, in San Francisco.

  • Business Wire2 months ago

    AgeX Therapeutics to Present at Master Investor Show 2019

    AgeX Therapeutics, Inc. , a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019, in association with Fidelity International, on Saturday, April 6 in London, England.

  • Business Wire3 months ago

    AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update

    ALAMEDA, Calif.-- -- Ends 2018 with triad of innovative cell therapy technologies: UniverCyte™ for immune tolerance, PureStem ® for cell derivation and manufacturing, and HyStem ® for cell delivery Potential to generate any human cell type with clinical and commercial friendly characteristics of hypoimmunogenicity, low COGS and availability off-the-shelf Juvenescence increased ownership by paying BioTime, ...

  • Business Wire3 months ago

    AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants

    AgeX Therapeutics, Inc. (“AgeX”, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that it has received $4.5 million from the exercise of AgeX common stock warrants. Warrant holders purchased a total of 1,800,000 shares of AgeX common stock through the exercise of warrants at an exercise price of $2.50 per share. The warrants were issued to investors by AgeX during 2018.

  • Business Wire3 months ago

    AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany

    AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that the company will present in multiple sessions at Undoing Aging 2019, March 28-30 in Berlin, Germany. Thursday, March 28, 7:00pm CET: “Debate: is comprehensive damage repair feasible?” with Aubrey de Grey, Ph.D., AgeX’s VP, New Technology Discovery and Vadim Gladyshev, Ph.D., Professor of Medicine at Harvard Medical School. Friday, March 29, 10:00am CET: As part of the track “Restoring Cellular Youth,” AgeX’s Founder and CEO Michael D. West, Ph.D., will deliver an update on the Company’s regenerative medicine product development, and in addition, present for the first time data relating to central molecular aging clockwork mechanisms the Company is targeting with its induced Tissue Regeneration (iTRTM) program.

  • Business Wire3 months ago

    LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration

    LifeMap Sciences (“LifeMap”), a subsidiary of AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that it has entered into a collaboration with iCarbonX Research Shenzhen, enabling iCarbonX to leverage LifeMap’s GeneCards® Suite platform in product prototype design and scientific research. LifeMap Sciences is a leading biomedical knowledgebase company that commercializes the popular GeneCards Suite, including GeneCards®, the Human Gene Compendium, MalaCards®, the Human Disease Database, as well as sophisticated analytic tools based on the comprehensive suite. LifeMap’s user base includes more than four million researchers world-wide and its customers include top-tier pharma and biotech customers.

  • GlobeNewswire4 months ago

    BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two affiliated companies, OncoCyte Corporation (OncoCyte) (NYSE American: OCX), and Asterias Biotherapeutics, Inc. (Asterias) (NYSE American: AST). “In the past five months, BioTime has made rapid progress toward its commitment to become a leading cell therapy company by focusing on clinical-stage cell therapy product candidates with promising human data and supporting their development in part through targeted transactions among its affiliated companies,” stated Brian M. Culley, Chief Executive Officer of BioTime, Inc.

  • Business Wire5 months ago

    AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London

    AgeX Therapeutics, Inc. , a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that the company will present at Longevity Leaders, February 4 in London, United Kingdom.

  • Business Wire5 months ago

    AgeX Therapeutics’ CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019

    AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that Founder and CEO Michael D. West, Ph.D. presented at Precision Medicine World Conference 2019, January 21 in Silicon Valley. Dr. West’s presentation was part of the Emerging Therapeutics Showcase. Dr. West described the unique properties of pluripotent stem cells, such as replicative immortality and the potential to become any of the cell types in the body, and the implications for the future of precision medicine.

  • Business Wire5 months ago

    LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market

    ALAMEDA, Calif.-- -- Novogene Tianjin to offer end-to-end sequencing through interpretation and reporting by integrating LifeMap’s leading TGex Clinical NGS tertiary analysis platform with their sequencing and bioinformatics services in China Partnership to expand LifeMap’s access to the Chinese Market LifeMap Sciences, Inc., a subsidiary of AgeX Therapeutics , Inc. announced today that Tianjin Novogene ...

  • Business Wire5 months ago

    AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity

    ALAMEDA, Calif.-- -- 30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels found in young adults Loss of brown fat as a result of aging is associated with obesity ...

  • GlobeNewswire5 months ago

    BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts, M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective January 7, 2019. "I’m excited to welcome Brandi to the BioTime team during this critical period in which we increase the focus on our clinical-stage product candidates and improve our business structure through recently-announced and pending transactions involving our affiliated companies, AgeX (NYSE American: AGE) and Asterias (NYSE American: AST),” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • Business Wire6 months ago

    AgeX Therapeutics to Present at Biotech Showcase 2019

    AgeX Therapeutics, Inc. , a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase, to be held January 7-9, 2019 in San Francisco, California.